Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism

Pivonello et al. • 2019

American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress